Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on...
-
Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved Leverage Ratio of 2.8x at Year-End, Below...
-
TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on...
-
TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and Dramamine®. Seventy-five years later, Dramamine, a Prestige Consumer...
-
Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings...
-
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate...
-
TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday,...
-
TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine...
-
TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate...
-
Revenue of $286.3 Million in Q2, Ahead of OutlookDiluted EPS of $1.07 in Q2, Up Over 5% Versus Prior YearReduced Leverage Ratio to 3.0x at Quarter EndReaffirming Full-Year Fiscal 2024 Revenue,...